Figwort (Scrophularia nodosa)
What Is Figwort?
Figwort is catalogued in the Materia Medica under the binomial Scrophularia nodosa, a plant of the Scrophulariaceae family, native to the temperate Northern Hemisphere. The material in circulation is aerial parts, root — an underground part, harvested once the plant has drawn its reserves down. Most people search for it simply as Figwort; suppliers, pharmacopoeias and interaction databases list it as Scrophularia nodosa, and matching the two is the first step in identifying what is actually in a product. In the hand it reads as mildly unpleasant, somewhat rank, bitter — a practical marker of freshness and correct identification.
The written history of Figwort begins with household and practitioner use — recipes, harvesting notes and cautions passed between regions — and only much later with laboratory description of what the aerial parts, root contains. Beyond its practical use it carries cultural associations — named for 'scrofula' — the King's Evil — once treated by royal touch and associated with clearing ancestral disease patterns.
Today most searches for Figwort come from people reading about eczema, psoriasis, circulation and energy, or checking how it sits alongside a medication they already take. The use most often documented in the literature is lymphatic alterative — clears chronic skin conditions, followed by anti-inflammatory iridoids (harpagoside, harpagide).
How Does Figwort Work?
Figwort works as a mixture rather than a single isolated compound, and its profile is usually described by the class of constituents present in aerial parts, root rather than by one marker molecule.
Traditional practice described Figwort in terms of taste, warmth and preparation rather than molecules — a working vocabulary that predicted which extractions were worth making long before any compound was isolated.
Published research is limited, leaning on small trials, laboratory work and animal models, and this profile cites 2 sources. Reported findings centre on iridoid content (harpagoside) links to Devil's Claw pharmacology. Where research exists, it examines lymphatic alterative — clears chronic skin conditions, anti-inflammatory iridoids (harpagoside, harpagide) and mild cardiotonic and diuretic. These are areas of study, not established outcomes, and results differ by preparation and dose.
How the plant is prepared changes what you actually get. Its constituents move readily into water and alcohol — so a preparation made in another medium will not carry the same fraction of the plant, which is why traditional recipes specify one over another.
The reason Figwort is treated as its own entry rather than a substitute for a related plant is proportion: related species share several of these compound classes, but not in the same ratio or concentration.
Because these constituents are processed by the same pathways that handle many medicines, Figwort is documented as interacting with cardiac glycosides (digoxin) and warfarin. That is a question of shared metabolism rather than of potency, and it is the main reason the plant is listed in interaction references at all.
Dose, plant part and growing conditions all shift the constituent profile, so two products carrying the name Figwort can differ substantially; this is why reference entries specify aerial parts, root and, where they exist, standardisation markers.